Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SELLAS Life Sciences Group ( (SLS) ) has issued an announcement.
SELLAS Life Sciences Group, Inc., a biopharmaceutical developer of cancer therapies, continues to build its capital base through the exercise of outstanding common stock warrants. The company focuses on novel oncology treatments for hematologic cancers and solid tumors, aiming to advance its clinical programs and strengthen its position in the life sciences sector.
Between December 31, 2025 and March 11, 2026, SELLAS raised approximately $42.6 million in gross proceeds from the exercise of common stock warrants, with about $26.5 million received by January 8, 2026 and an additional $16.1 million thereafter. As of March 11, 2026, the company had 179,536,724 shares of common stock outstanding, reflecting the equity issuance tied to these warrant exercises and signaling an enhanced cash position for ongoing operations and development efforts.
The most recent analyst rating on (SLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SELLAS Life Sciences Group stock, see the SLS Stock Forecast page.
Spark’s Take on SLS Stock
According to Spark, TipRanks’ AI Analyst, SLS is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses, minimal revenue, and persistent cash burn). This is partially offset by strong technical momentum (uptrend across major moving averages with positive MACD) and a liquidity boost from the recent financing event, though dilution risk remains. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on SLS stock, click here.
More about SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing innovative cancer therapies. The company operates in the life sciences industry, leveraging immunotherapy and other advanced modalities to target hematologic malignancies and solid tumors in global oncology markets.
Average Trading Volume: 9,022,328
Technical Sentiment Signal: Buy
Current Market Cap: $829M
Learn more about SLS stock on TipRanks’ Stock Analysis page.